Abstract
Neurotensin receptors are overexpressed in several human tumors and can be targets for tumors diagnosis and therapy. In this study, a new neurotensin analogue was labeled with 99mTc via HYNIC and tricine/EDDA as coligands and investigated further. [HYNIC0, Gly7, Lys9, d-Tyr11]-Neurotensin (7–13) was synthesized using a standard Fmoc strategy. Labeling with 99mTc was performed at 100 °C for 10 min and radiochemical analysis involved ITLC and HPLC methods. The stability of radiopeptide was checked in the presence of humane serum at 37 °C up to 24 h. The receptor bound internalization and externalization rates were studied in neurotensin receptor expressing HT-29 cells. Biodistribution of radiopeptide was studied in nude mice bearing HT-29 tumor. Labeling yield of 98.6 ± 0.54 % (n = 3) was obtained corresponding to a specific activity of 81 MBq/nmol. Peptide conjugate showed good stability in the presence of human serum. The radioligand showed specific internalization into HT-29 cells (12.43 ± 0.52 % at 4 h). In biodistribution studies, a receptor-specific uptake was observed in neurotensin receptor positive organs so that after 1 h the uptakes in mouse intestine and tumor were 0.87 ± 0.16 and 0.63 ± 0.12 % ID/g respectively.
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs10967-013-2795-1/MediaObjects/10967_2013_2795_Fig1_HTML.gif)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs10967-013-2795-1/MediaObjects/10967_2013_2795_Fig2_HTML.gif)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs10967-013-2795-1/MediaObjects/10967_2013_2795_Fig3_HTML.gif)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs10967-013-2795-1/MediaObjects/10967_2013_2795_Fig4_HTML.gif)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs10967-013-2795-1/MediaObjects/10967_2013_2795_Fig5_HTML.gif)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs10967-013-2795-1/MediaObjects/10967_2013_2795_Fig6_HTML.gif)
Similar content being viewed by others
References
Reubi JC (1995) J Nucl Med 36:1825
Okarvi SM (2004) Med Res Rev 24(3):357
Hoffman TJ, Quinn TP, Volkert WA (2001) Nucl Med Biol 28(5):527
Reubi JC (2003) Endocr Rev 24:389
Morinville A, Martin S, Lavallee M, Vincent JP, Beaudet A, Mazella J (2004) Int J Biochem Cell Biol 36:2153
Kitabgi P (2002) Curr Opin Drug Discov Devel 5:764
Vincent JP, Mazella J, Kitabgi P (1999) Trends Pharmacol Sci 20:302
Reubi JC, Maecke HR, Krenning EP (2005) J Nucl Med 46:67
Reubi JC, Waser B, Friess H, Buchler M, Laissue J (1998) Gut 42:546
Achilefu S, Srinivasan A, Schmidt MA, Jimenez HN, Bugaj JE, Erion JL (2003) J Med Chem 46:3403
Garcia-Garayoa E, Allemann-Tannahill L, Blauenstein P, Willmann M, Carell-remy N, Tourwe D, Iterbeke K, Conrath P, Schubiger PA (2001) Nucl Med Biol 28:75
Kokko KP, Hadden MK, Orwig KS, Mazella J, Dix TA (2003) J Med Chem 46:4141
Lundquist JT, Dix TA (1999) Biorg Med Chem Lett 9:2579
Hong F, Zaidi J, Cusack B, Richelson E (2002) Bioorg Med Chem 10:3849
Kitabgi P, De Nadai F, Rovere C, Bidard JN (1992) Ann N Y Acad Sci 668:30
Davis TP, Konings PNM (1993) Crit Rev Neurobiol 7:163
Garcıa-Garayoa E, Maes V, Blauenstein P, Blanc A, Hohn A, Tourwe D, Schubiger PA (2006) Nucl Med Biol 33:495
Heyl D, Sefler NM, He JX, Sawyer TK, Wustrow DJ, Akunne HC, Davis MD, Pugsley TP, Heffner TG, Corbin AE, Cody WL (1994) Chem Biol Drug Des 44:233
Hoffman TJ, Gali H, Smith VJ, Siekman GL, Hayes DL, Owen NK, Volkert WA (2003) J Nucl Med 44:823
Bergmann R, Scheunemann M, Heichert C, Mding P, Wittrisch H, Kretzschmar M, Rodig H, Tourwe D, Iterbeke K, Chavatte K, Zips D, Reubi JC, Johannsen B (2002) Nucl Med Biol 29:61
Hoffman TJ, Li N, Volkert WA, Sieckman GL, Higginbotham C, Ochrymowcycz LA (1997) J Label Compd Radiopharm 40:490
Garcıa-Garayoa E, Blauenstein P, Blanc A, Maes V, Tourwe D, Schubiger PA (2009) Eur J Nucl Med Mol Imaging 36(1):37
Schubiger PA, Allemann-Tannahill L, Egli A, Schibli R, Alberto R, Carel-Remy N, Willmann M, Blauenstein P, Tourwe D (1999) Q J Nucl Med Mol Imaging 43:155
Teodoro R, Faintuch BL, Nunez EGF, Queiroz RG (2011) Nucl Med Biol 38:113
Maina T, Nikolopoulou A, Stathopoulou E, Galanis AS, Cordopatis P, Nock BA (2007) Eur J Nucl Med Mol Imaging 34:1804
Abrams MJ, Juweid M, tenKate CI, Schwartz DA, Hauser MM, Gaul FE, Fuccello AJ, Rubin RH, Strauss W, Fischman AJ (1990) J Nucl Med 31:2022
Faintuch BL, Santos RLSR, Souza ALFM, Hoffman TJ, Greeley M, Smith CJ (2005) Chemistry 35:43
Gandomkar M, Najafi R, Shafiei M, Mazidi M, Ebrahimi SES (2007) Nucl Med Biol 34:651
Sadeghzadeh N, Gandomkar M, Najafi R, Shafiei M, Sadat Ebrahimi SE, Shafiee A, Larijani B (2010) J Radioanal Nucl Chem 283:181
Sadeghzadeh N, Gandomkar M, Shafiee M, Mazidi M, Goudarzi M, Mirfallah SM, Sadat Ebrahimi SE (2009) Iran J Nucl Med 17(1):18
Atherton E, Sheppard R (1989) Fluorenylmethoxycarbonyl-poly-amide solid phase peptide synthesis—general principles and development. In: Solid phase peptide synthesis. A practical approach, Oxford Information Press, Oxford, p 25–38
Maina T, Nock B, Nikolopoulou A (2002) Eur J Nucl Med Mol Imaging 29:742
Erfani M, Shafiei M, Mazidi M, Goudarzi M (2013) Cancer Biother Radiopharm 28(3):240
Shirmardi SP, Gandomkar M, Mazidi M, Shafiei M, Ghannadi Maragheh M (2011) J Radioanal Nucl Chem 288:327
Shirmardi SP, Gandomkar M, Ghannadi Maragheh M, Shamsaei M (2011) Cancer Biother Radiopharm 26(3):309
Liu S, Edwards DS, Looby RJ, Poirier MJ, Rajopadhye M, Bourque JP, Carroll TR (1996) Bioconjug Chem 7(2):196
Kasina S, Rao T, Srinivasan A, Sanderson JA, Fitzner JN, Reno JM, Beaumier PL, Fritzberg AR (1991) J Nucl Med 32:1445
Maina T, Stolz B, Albert R, Bruns C, Koch P, Maecke HR (1994) Eur J Nucl Med 21(5):437
Yurt Lambrecht F, Durkan K, Ozgur A, Gunduz C, Avci CB, Susluer SY (2013) J Drug Target 21(4):383
Yurt Lambrecht F, Durkan K, Bayrak E (2010) J Radioanal Nucl Chem 284:539
Liu S, Edwards DS, Looby RJ, Harris AR, Poirier MJ, Barrett JA, Heminway SJ, Carrol TR (1996) Bioconj Chem 7:63
Gabriel M, Froehlich F, Decristoforo C, Ensinger C, Donnemiller E, von Guggenberg E, Heute D, Moncayo R (2004) Eur J Nucl Med Mol Imaging 31:330
Babich JW, Fischman AJ (1995) Nucl Med Biol 22(1):25
Nock BA, Nikolopoulou A, Reubi JC, Maes V, Conrath P, Tourwe D, Maina T (2006) J Med Chem 49:4767
Tanaka K, Masu M, Nakanishi S (1996) Neuron 4:847
Mule F, Serio R, Postorino A, Vetri T, Bonvissuto F (1996) Br J Pharmacol 117:488
Bidard JN, Nadai F, Rovere C, Moinier D, Laur J, Martinez J, Cuber JC, Kitabgi P (1993) Biochem J 291:225
Acknowledgments
The authors wish to thank Mr. Mirfallah and Mr. Talebi of the Radioisotope Department (AEOI) for providing sodium pertechnetate and assistance in quality control tests.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ahrabi, N.Z., Erfani, M., Parivar, K. et al. Preparation and evaluation of a new neurotensin analog labeled with 99mTc for targeted imaging of neurotensin receptor positive tumors. J Radioanal Nucl Chem 299, 461–469 (2014). https://doi.org/10.1007/s10967-013-2795-1
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10967-013-2795-1